We have known for some time that Medtronic has been exploring multiple options for its struggling diabetes unit. Among the options being considered were a possible sale of the unit or combining the unit with another franchise and then spinning this combined entity off as separate publicly traded company. Our guess was a sale would involve private equity, the sticking point, excuse the expression would be how Medtronic valued the unit. The unit may be struggling but it is still the market leader in insulin pumps when it comes to installed user base and it does generate a healthy and . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.